Title:
TREATMENT OF SEVERE PNEUMONIA BY ADMINISTRATION OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI)
Document Type and Number:
WIPO Patent Application WO2003032904
Kind Code:
A3
Abstract:
Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.
More Like This:
Inventors:
CREASEY ABLA A (US)
Application Number:
PCT/US2002/032624
Publication Date:
March 04, 2004
Filing Date:
October 15, 2002
Export Citation:
Assignee:
CHIRON CORP (US)
CREASEY ABLA A (US)
CREASEY ABLA A (US)
International Classes:
A61K9/08; A61K9/19; A61K31/727; A61K38/00; A61K38/16; A61K38/43; A61K38/55; A61K38/57; A61K39/395; A61K45/00; A61K47/12; A61K47/16; A61K47/18; A61P29/00; A61P31/04; A61K; (IPC1-7): A61K38/16
Foreign References:
| US5212091A | 1993-05-18 | |||
| US5563123A | 1996-10-08 |
Other References:
FELDMAN ET AL.: "Anti-TNF alpha therapy is useful iun rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other diseases", TRANSPLANTATION PROC., vol. 30, no. 8, December 1998 (1998-12-01), pages 4126 - 4127, XP002098301
GUNTHER ET AL.: "Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome", AN. J. PRESPIR. CRIT. CARE. MED., vol. 161, no. 2, PT. 1, February 2000 (2000-02-01), pages 454 - 462, XP002973713
GUNTHER ET AL.: "Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome", AN. J. PRESPIR. CRIT. CARE. MED., vol. 161, no. 2, PT. 1, February 2000 (2000-02-01), pages 454 - 462, XP002973713
Download PDF: